Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.
Kubo K, Ohara M, Tachikawa M, Cavallari LH, Lee MTM, Wen MS, Scordo MG, Nutescu EA, Perera MA, Miyajima A, Kaneko N, Pengo V, Padrini R, Chen YT, Takahashi H. Kubo K, et al. Among authors: pengo v. Pharmacogenomics J. 2017 Dec;17(6):494-500. doi: 10.1038/tpj.2016.57. Epub 2016 Aug 9. Pharmacogenomics J. 2017. PMID: 27503578
Apolipoprotein E (APOE) and warfarin dosing in an Italian population.
Kohnke H, Scordo MG, Pengo V, Padrini R, Wadelius M. Kohnke H, et al. Among authors: pengo v. Eur J Clin Pharmacol. 2005 Nov;61(10):781-3. doi: 10.1007/s00228-005-0982-x. Epub 2005 Aug 26. Eur J Clin Pharmacol. 2005. PMID: 16133550 No abstract available.
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.
Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H. Takahashi H, et al. Among authors: pengo v. Pharmacogenet Genomics. 2006 Feb;16(2):101-10. doi: 10.1097/01.fpc.0000184955.08453.a8. Pharmacogenet Genomics. 2006. PMID: 16424822
Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, Langaee T, Siguret V, Loriot MA, Sagreiya H, Altman RB, Shahin MH, Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C. Danese E, et al. Among authors: pengo v. Clin Pharmacol Ther. 2012 Dec;92(6):746-56. doi: 10.1038/clpt.2012.184. Epub 2012 Nov 7. Clin Pharmacol Ther. 2012. PMID: 23132553 Free PMC article. Review.
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation.
Pengo V, Zambon CF, Fogar P, Padoan A, Nante G, Pelloso M, Moz S, Frigo AC, Groppa F, Bozzato D, Tiso E, Gnatta E, Denas G, Padayattil Jose S, Padrini R, Basso D, Plebani M. Pengo V, et al. PLoS One. 2015 Dec 28;10(12):e0145318. doi: 10.1371/journal.pone.0145318. eCollection 2015. PLoS One. 2015. PMID: 26710337 Free PMC article. Clinical Trial.
459 results